Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously supporting the fast, efficient workflows needed in modern operating rooms (ORs).

“Building on over 15 years of experience in the femtocataract laser market, our goal was to deliver a platform that provides both enhanced functionality and greater flexibility to the OR,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “SeeLyra delivers, helping surgeons achieve the precise preparation and controlled conditions necessary to unlock the full potential of premium cataract surgery without compromising on space or efficiency.”

SeeLyra features integrated tools that provide accuracy and control. Live swept source OCT provides real-time depth-visualization throughout the procedure, helping to reduce variability during docking while enabling precise positioning of laser cuts and visual control during laser application. SeeLyra also retains vital, highly appreciated features of VICTUS^™, the previous-generation Bausch + Lomb femtosecond platform, such as an intuitive user interface designed to streamline setup and adaptability for a wide range of procedures including cataract, LASIK flap and corneal therapeutic treatments.

Compact design and the absence of a fixed patient bed, as well as compatibility with existing bed setups, allows for the flexible positioning and easy transport of SeeLyra across modern, space-constrained OR environments. The absence of a fixed bed also contributes to patient comfort, eliminating the need to switch beds between procedures. An articulating swing arm accommodates surgeons’ preferred orientation for performing surgery.

“Premium surgery success begins with precise surgical preparation of the eye,” said José Manuel Larrosa, MD, University of Zaragoza, Spain. “SeeLyra will help me to achieve this consistently on my terms, while fitting seamlessly and efficiently into our OR space and workflow.”

SeeLyra will be available in Europe on a limited basis in the coming months, with increasing availability expected in 2027. Bausch + Lomb is also in the process of seeking regulatory approvals for SeeLyra in markets around the world, including the United States. Indications and approvals may vary by country.